These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1543 related articles for article (PubMed ID: 28179575)

  • 1. Key Lessons Learned from Moffitt's Molecular Tumor Board: The Clinical Genomics Action Committee Experience.
    Knepper TC; Bell GC; Hicks JK; Padron E; Teer JK; Vo TT; Gillis NK; Mason NT; McLeod HL; Walko CM
    Oncologist; 2017 Feb; 22(2):144-151. PubMed ID: 28179575
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Integrating Genomics Into Clinical Pediatric Oncology Using the Molecular Tumor Board at the Memorial Sloan Kettering Cancer Center.
    Ortiz MV; Kobos R; Walsh M; Slotkin EK; Roberts S; Berger MF; Hameed M; Solit D; Ladanyi M; Shukla N; Kentsis A
    Pediatr Blood Cancer; 2016 Aug; 63(8):1368-74. PubMed ID: 27082517
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cancer genomics guide clinical practice in personalized medicine.
    Lehmann-Che J; Poirot B; Boyer JC; Evrard A
    Therapie; 2017 Sep; 72(4):439-451. PubMed ID: 28258721
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Precision Oncology and "Molecular Tumor Boards" - Concepts, Chances and Challenges].
    Holch JW; Westphalen CB; Hiddemann W; Heinemann V; Jung A; Metzeler KH
    Dtsch Med Wochenschr; 2017 Nov; 142(22):1676-1684. PubMed ID: 29078213
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Experience with precision genomics and tumor board, indicates frequent target identification, but barriers to delivery.
    Bryce AH; Egan JB; Borad MJ; Stewart AK; Nowakowski GS; Chanan-Khan A; Patnaik MM; Ansell SM; Banck MS; Robinson SI; Mansfield AS; Klee EW; Oliver GR; McCormick JB; Huneke NE; Tagtow CM; Jenkins RB; Rumilla KM; Kerr SE; Kocher JA; Beck SA; Fernandez-Zapico ME; Farrugia G; Lazaridis KN; McWilliams RR
    Oncotarget; 2017 Apr; 8(16):27145-27154. PubMed ID: 28423702
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Strategies to overcome clinical, regulatory, and financial challenges in the implementation of personalized medicine.
    Tsimberidou AM; Ringborg U; Schilsky RL
    Am Soc Clin Oncol Educ Book; 2013; ():118-25. PubMed ID: 23714475
    [TBL] [Abstract][Full Text] [Related]  

  • 7. AACR precision medicine series: Highlights of the integrating clinical genomics and cancer therapy meeting.
    Maggi E; Montagna C
    Mutat Res; 2015 Dec; 782():44-51. PubMed ID: 26554403
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Initiative for Molecular Profiling and Advanced Cancer Therapy and challenges in the implementation of precision medicine.
    Tsimberidou AM
    Curr Probl Cancer; 2017; 41(3):176-181. PubMed ID: 28410846
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Precision medicine in pediatric oncology: Lessons learned and next steps.
    Mody RJ; Prensner JR; Everett J; Parsons DW; Chinnaiyan AM
    Pediatr Blood Cancer; 2017 Mar; 64(3):. PubMed ID: 27748023
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Implementation of a Molecular Tumor Board: The Impact on Treatment Decisions for 35 Patients Evaluated at Dartmouth-Hitchcock Medical Center.
    Tafe LJ; Gorlov IP; de Abreu FB; Lefferts JA; Liu X; Pettus JR; Marotti JD; Bloch KJ; Memoli VA; Suriawinata AA; Dragnev KH; Fadul CE; Schwartz GN; Morgan CR; Holderness BM; Peterson JD; Tsongalis GJ; Miller TW; Chamberlin MD
    Oncologist; 2015 Sep; 20(9):1011-8. PubMed ID: 26205736
    [TBL] [Abstract][Full Text] [Related]  

  • 11. From somatic variants towards precision oncology: Evidence-driven reporting of treatment options in molecular tumor boards.
    Perera-Bel J; Hutter B; Heining C; Bleckmann A; Fröhlich M; Fröhling S; Glimm H; Brors B; Beißbarth T
    Genome Med; 2018 Mar; 10(1):18. PubMed ID: 29544535
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Precision medicine in oncology].
    Mack E
    Inn Med (Heidelb); 2024 Mar; 65(3):194-201. PubMed ID: 37921995
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Defining precision: The precision medicine initiative trials NCI-MPACT and NCI-MATCH.
    Coyne GO; Takebe N; Chen AP
    Curr Probl Cancer; 2017; 41(3):182-193. PubMed ID: 28372823
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A clinical pharmacy pilot within a Precision Medicine Program for cancer patients and review of related pharmacist clinical practice.
    Arnall JR; Petro R; Patel JN; Kennedy L
    J Oncol Pharm Pract; 2019 Jan; 25(1):179-186. PubMed ID: 29078708
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Precision medicine in oncology: New practice models and roles for oncology pharmacists.
    Walko C; Kiel PJ; Kolesar J
    Am J Health Syst Pharm; 2016 Dec; 73(23):1935-1942. PubMed ID: 27864201
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evolving landscape of tumor molecular profiling for personalized cancer therapy: a comprehensive review.
    Syn NL; Yong WP; Goh BC; Lee SC
    Expert Opin Drug Metab Toxicol; 2016 Aug; 12(8):911-22. PubMed ID: 27249175
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A framework to rank genomic alterations as targets for cancer precision medicine: the ESMO Scale for Clinical Actionability of molecular Targets (ESCAT).
    Mateo J; Chakravarty D; Dienstmann R; Jezdic S; Gonzalez-Perez A; Lopez-Bigas N; Ng CKY; Bedard PL; Tortora G; Douillard JY; Van Allen EM; Schultz N; Swanton C; André F; Pusztai L
    Ann Oncol; 2018 Sep; 29(9):1895-1902. PubMed ID: 30137196
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Molecular-Genetic Diagnosis and Molecular-Targeted Therapy in Cancer: Challenges in the Era of Precision Medicine].
    Miyachi H
    Rinsho Byori; 2015 Oct; 63(10):1188-93. PubMed ID: 26897855
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Precision medicine: In need of guidance and surveillance.
    Lin JZ; Long JY; Wang AQ; Zheng Y; Zhao HT
    World J Gastroenterol; 2017 Jul; 23(28):5045-5050. PubMed ID: 28811702
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Unlocking the potential of Molecular Tumor Boards: from cutting-edge data interpretation to innovative clinical pathways.
    Pastò B; Buzzatti G; Schettino C; Malapelle U; Bergamini A; De Angelis C; Musacchio L; Dieci MV; Kuhn E; Lambertini M; Passarelli A; Toss A; Farolfi A; Roncato R; Capoluongo E; Vida R; Pignata S; Callari M; Baldassarre G; Bartoletti M; Gerratana L; Puglisi F
    Crit Rev Oncol Hematol; 2024 Jul; 199():104379. PubMed ID: 38718940
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 78.